Archives of Clinical Infectious Diseases
Infectious Diseases and Tropical Medicine Research Center, SBUMS
Authors
Most therapeutic interventions in acute phase of viral hepatitis B patients are conservative. Prostaglandins have absorbed many scientists' attention for improving these patients condition, therefore, the present study was designed to evaluate misoprostol (PGE1 Analogue) effect on acute phase of viral hepatitis B.
A randomized matched controlled clinical trial was performed on two equal groups each included fifteen male acute phase hepatitis B patients who were anti HBC IgM and HBs Ag positive, hepatitis C negative and their total bilirubin level was more than 10 mg/dl. The experimental group received 800?g misoprostole (200?g 4 times a day) while the control group received placebo for 14 days. Their bilirubin and serum transaminases concentrations as well as PT and PTT were checked before and after the therapy and compared by chi square and tstudent tests using SPSS software.
At the end of the treatment phase, serum bilirubin, SGPT and PTT were significantly lower in the experimental group. After three weeks follow up, only SGOT was not significantly lower in experimental group. At the end of the 4th and the 5th week after treatment initiation, serum bilirubin, SGPT, alkaline phosphatase and PTT were significantly lower in experimental group.
These results confirm that misoprostol improves hepatitis B patients' condition and reduces their serum bilirubin, SGPT, alkaline phosphatase and PTT.
© 2006, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Alavian SM, Miri SM, Behzadnia MJ. Hepatitis B Virus DNA Level as Predictor of Response to Therapy with Interferon-alpha-2b (PDferon) in Chronic Hepatitis B Infection. Arch Clin Infect Dis. 2011;6(1):. doi:
Sali S, Nasiri M. Tenofovir Response Rate and Adverse Effects in Patients with Chronic Hepatitis B Attending to Hepatitis Clinic at Labbafinejad Hospital. Jundishapur J Nat Pharm Prod. 2019;14(3):e63023. doi: https://doi.org/10.5812/jjnpp.63023
Pouresmaeeli M, Alavian SM, Keshvari M, Salimi S, Mehrnoush L. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C. Hepat Mon. 2015;15(9):e30780. doi: https://doi.org/10.5812/hepatmon.30780
Bahcecioglu IH, Ispiroglu M, Demirel U, Yalniz M. Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience. Hepat Mon. 2015;15(3):e24366. doi: https://doi.org/10.5812/hepatmon.24366
Alavian S, E, H, B, N, et al. Hepatitis in The World. Hepat Mon. 2003;1(1):. doi:
Last Update: 3 weeks ago
Last Update: 3 weeks ago
Last Update: 3 weeks ago
Last Update: 18 hours ago
Last Update: 1 day ago
Last Update: 4 days ago